Lipka, Daniel B <br/><br/>
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.  [electronic resource] 

 -  Nature communications  12 2017 
 - 2126 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2041-1723 
<br/><br/><label>Standard No.: </label>10.1038/s41467-017-02177-w  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Biopsy<br/>Child<br/>Child, Preschool<br/>Chromatin--genetics<br/>DNA (Cytosine-5-)-Methyltransferase 1--metabolism<br/>DNA (Cytosine-5-)-Methyltransferases--metabolism<br/>DNA Methylation<br/>DNA Mutational Analysis<br/>Epigenomics<br/>Female<br/>Gene Expression Regulation, Leukemic<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Infant<br/>Leukemia, Myelomonocytic, Juvenile--genetics<br/>Male<br/>Mutation<br/>Noonan Syndrome--genetics<br/>Prognosis<br/>Prospective Studies<br/>Protein Tyrosine Phosphatase, Non-Receptor Type 11--genetics<br/>Proto-Oncogene Proteins c-cbl<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Signal Transduction--genetics<br/>Up-Regulation<br/>DNA Methyltransferase 3B